Related Experiment Video
Updated: Dec 25, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer
Yuping Yang1, Yue Qiu2, Xu Liu2
1School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China.
Abstract:
Kinase-targeted therapy has been widely used as a lifesaving strategy for cancer patients. However, many patients treated with targeted cancer drugs are clinically observed to rapidly develop acquired resistance. Kinase gatekeeper mutation is one of the most chief factors contributing to the resistance, which modulates the accessibility of kinase's ATP-binding pocket. Previously, the pan-kinase inhibitor Staurosporine and its analogs (termed as Staralogs) have been reported to exhibit wild-type sparing selectivity for some kinase gatekeeper mutants, such as EGFR T790M, Her2 T798M and cSrc T338M. Here, we describe an integrative approach to systematically profile the molecular response of 15 representative Staralogs to 17 kinase gatekeeper mutations in targeted cancer therapy. With the profile we are able to divide gatekeeper mutations into three classes (i.e. classes I, II and III) and to divide Staralogs into two groups (i.e. groups 1 and 2) using heuristic clustering. The class I and II mutations confer consistent sensitivity and resistance for all Staralogs, respectively, while the class III mutations address divergent effects on different Staralogs. The mutations to Ile residue can generally reduce Staralog affinity by inducing unfavorable steric hindrance, whereas the mutations to Met and Leu residues would improve Staralog affinity by establishing favorable S···π interaction, van der Waals packing and/or hydrophobic contact. The group 1 and 2 Staralogs are primarily determined by carbonyl or hydroxyl substitution state at the position 7 of Staralog core, where points to kinase gatekeeper residue and can thus be directly influenced by gatekeeper mutation.
Insights
Acquired resistance to kinase-targeted cancer therapy is often caused by gatekeeper mutations. This study classifies mutations and Staurosporine analogs (Staralogs) to predict drug response and overcome resistance.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Kinase-targeted therapy is crucial for cancer treatment but frequently encounters acquired resistance.
- Kinase gatekeeper mutations, altering ATP-binding pocket accessibility, are a primary cause of this resistance.
- Staurosporine analogs (Staralogs) have shown selective activity against some gatekeeper mutants.
Purpose of the Study:
- To systematically profile the molecular response of 15 Staralogs to 17 kinase gatekeeper mutations.
- To develop a classification system for gatekeeper mutations and Staralogs to predict therapeutic outcomes.
- To understand the structural basis for Staralog interactions with gatekeeper mutants.
Main Methods:
- Heuristic clustering was employed to classify 17 kinase gatekeeper mutations into three classes (I, II, III) and 15 Staralogs into two groups (1, 2).
- Analysis of mutation-induced changes in Staralog affinity, considering steric hindrance and favorable interactions (S···π, van der Waals, hydrophobic).
- Correlation of Staralog group classification with specific structural features, particularly substitution at position 7 of the Staralog core.
Main Results:
- Gatekeeper mutations were classified into Class I (consistent sensitivity), Class II (consistent resistance), and Class III (divergent effects) across all Staralogs.
- Mutations to Ile generally decreased Staralog affinity due to steric hindrance.
- Mutations to Met and Leu enhanced Staralog affinity through favorable interactions, while Staralog groups were determined by substitution at position 7.
Conclusions:
- A systematic profiling approach successfully classified gatekeeper mutations and Staralogs, providing a framework for predicting drug response.
- Understanding the impact of specific gatekeeper mutations (Ile, Met, Leu) on Staralog binding is key to overcoming resistance.
- The classification system aids in rational drug design and selection for targeted cancer therapy, potentially improving patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers